vs
CareDx, Inc.（CDNA）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是CareDx, Inc.的2.6倍（$281.3M vs $108.4M）。CareDx, Inc.净利率更高（-3.8% vs -45.7%，领先41.9%）。Guardant Health, Inc.同比增速更快（39.4% vs 25.2%）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 22.7%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
CDNA vs GH — 直观对比
营收规模更大
GH
是对方的2.6倍
$108.4M
营收增速更快
GH
高出14.2%
25.2%
净利率更高
CDNA
高出41.9%
-45.7%
两年增速更快
GH
近两年复合增速
22.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $108.4M | $281.3M |
| 净利润 | $-4.1M | $-128.5M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -5.6% | -43.0% |
| 净利率 | -3.8% | -45.7% |
| 营收同比 | 25.2% | 39.4% |
| 净利润同比 | -104.7% | -15.8% |
| 每股收益（稀释后） | $-0.08 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAGH
| Q4 25 | $108.4M | $281.3M | ||
| Q3 25 | $100.1M | $265.2M | ||
| Q2 25 | $86.7M | $232.1M | ||
| Q1 25 | $84.7M | $203.5M | ||
| Q4 24 | $86.6M | $201.8M | ||
| Q3 24 | $82.9M | $191.5M | ||
| Q2 24 | $92.3M | $177.2M | ||
| Q1 24 | $72.0M | $168.5M |
净利润CDNAGH
| Q4 25 | $-4.1M | $-128.5M | ||
| Q3 25 | $1.7M | $-92.7M | ||
| Q2 25 | $-8.6M | $-99.9M | ||
| Q1 25 | $-10.4M | $-95.2M | ||
| Q4 24 | $87.7M | $-111.0M | ||
| Q3 24 | $-10.6M | $-107.8M | ||
| Q2 24 | $-4.6M | $-102.6M | ||
| Q1 24 | $-19.9M | $-115.0M |
毛利率CDNAGH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
营业利润率CDNAGH
| Q4 25 | -5.6% | -43.0% | ||
| Q3 25 | -0.2% | -37.3% | ||
| Q2 25 | -12.8% | -45.9% | ||
| Q1 25 | -15.8% | -54.6% | ||
| Q4 24 | 97.5% | -62.4% | ||
| Q3 24 | -16.6% | -61.3% | ||
| Q2 24 | -7.9% | -56.8% | ||
| Q1 24 | -31.3% | -59.2% |
净利率CDNAGH
| Q4 25 | -3.8% | -45.7% | ||
| Q3 25 | 1.7% | -35.0% | ||
| Q2 25 | -9.9% | -43.0% | ||
| Q1 25 | -12.2% | -46.8% | ||
| Q4 24 | 101.3% | -55.0% | ||
| Q3 24 | -12.8% | -56.3% | ||
| Q2 24 | -5.0% | -57.9% | ||
| Q1 24 | -27.6% | -68.2% |
每股收益（稀释后）CDNAGH
| Q4 25 | $-0.08 | $-1.01 | ||
| Q3 25 | $0.03 | $-0.74 | ||
| Q2 25 | $-0.16 | $-0.80 | ||
| Q1 25 | $-0.19 | $-0.77 | ||
| Q4 24 | $1.60 | $-0.90 | ||
| Q3 24 | $-0.20 | $-0.88 | ||
| Q2 24 | $-0.09 | $-0.84 | ||
| Q1 24 | $-0.38 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.2M | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $303.1M | $-99.3M |
| 总资产 | $413.2M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAGH
| Q4 25 | $177.2M | $378.2M | ||
| Q3 25 | $194.2M | $580.0M | ||
| Q2 25 | $186.3M | $629.1M | ||
| Q1 25 | $230.9M | $698.6M | ||
| Q4 24 | $260.7M | $525.5M | ||
| Q3 24 | $240.9M | $585.0M | ||
| Q2 24 | $228.9M | $933.7M | ||
| Q1 24 | $215.9M | $1.0B |
总债务CDNAGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益CDNAGH
| Q4 25 | $303.1M | $-99.3M | ||
| Q3 25 | $311.1M | $-354.5M | ||
| Q2 25 | $327.4M | $-305.5M | ||
| Q1 25 | $379.3M | $-250.8M | ||
| Q4 24 | $378.4M | $-139.6M | ||
| Q3 24 | $273.2M | $-60.1M | ||
| Q2 24 | $264.7M | $-1.6M | ||
| Q1 24 | $256.2M | $68.3M |
总资产CDNAGH
| Q4 25 | $413.2M | $2.0B | ||
| Q3 25 | $432.3M | $1.3B | ||
| Q2 25 | $444.3M | $1.3B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.5B | ||
| Q3 24 | $477.0M | $1.5B | ||
| Q2 24 | $466.8M | $1.6B | ||
| Q1 24 | $452.4M | $1.7B |
负债/权益比CDNAGH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.4M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-54.2M |
| 自由现金流率自由现金流/营收 | — | -19.3% |
| 资本支出强度资本支出/营收 | — | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流CDNAGH
| Q4 25 | $21.4M | $-26.4M | ||
| Q3 25 | $37.4M | $-35.4M | ||
| Q2 25 | $9.9M | $-60.3M | ||
| Q1 25 | $-26.6M | $-62.7M | ||
| Q4 24 | $21.9M | $-64.5M | ||
| Q3 24 | $12.5M | $-51.1M | ||
| Q2 24 | $18.9M | $-94.0M | ||
| Q1 24 | $-15.3M | $-30.3M |
自由现金流CDNAGH
| Q4 25 | — | $-54.2M | ||
| Q3 25 | — | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
自由现金流率CDNAGH
| Q4 25 | — | -19.3% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
资本支出强度CDNAGH
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
现金转化率CDNAGH
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
